Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 6,400 shares, an increase of 1,180.0% from the March 15th total of 500 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 866,800 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Trading Up 3.7 %

PVCT opened at $0.10 on Wednesday. Provectus Biopharmaceuticals has a one year low of $0.04 and a one year high of $0.20. The business’s 50 day moving average price is $0.10 and its 200 day moving average price is $0.11.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.